Barchart Research What to Expect from STOK Earnings STOK Generated July 31, 2026 Current Price $28.86 EPS Estimate $$-0.82 Consensus Rating Strong Buy Average Move 6.33% Stoke Therapeutics Prepares to...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine,...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases–
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label...
– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the...